Back to Journals » International Journal of Women's Health » Volume 2

Profile of teriparatide in the management of postmenopausal osteoporosis

Authors Sikon A, Batur P

Published 31 March 2010 Volume 2010:2 Pages 37—44

DOI https://doi.org/10.2147/IJWH.S4919

Review by Single-blind

Peer reviewer comments 2


Andrea Sikon1, Pelin Batur2

1Cleveland Clinic Lerner COM, Cleveland Clinic, Cleveland, OH, USA; 2Cleveland Clinic Lerner COM, Cleveland Clinic Independence, Independence, OH, USA

Abstract: One out of every 2 women within postmenopause are at risk of fracture due to osteoporosis. Fortunately, a growing arsenal of therapies is becoming available to treat this disease and prevent fracture. A new class of anabolic agents has emerged within the last decade that brought with it a new concept in osteoporosis therapy: building new stronger bone rather than simply inhibiting bone turnover. Evidence is accumulating to understand how to best utilize these new agents, and which patients benefit most. This article will review the effectiveness, risks, timing and clinical uses of teriparatide in postmenopausal osteoporosis.
Keywords: osteoporosis, menopause, teriparatide

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]